Korczyn AD. Mixed dementia – the most common cause of dementia. Ann N Y Acad Sci Nov, 2002, 977: 129-34.

Langa KM, Foster NL, Larson EB. Mixed dementia: emerging concepts and therapeutic implications. JAMA, 2004 Dec 15, 292(23): 2901-8.

Korczyn AD, Vakhapova V. Is vascular cognitive impairment a useful concept? Journal of the Neurological Sciences, 2010, 299: 2-4.

Kalaria RN, Kenny RA, Ballard C et al. Towards defining of neuropathological substrates of vascular dementia. J. Neurol Sci., 2004, 226: 75-80.

Leys D, Неnon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol., 2005: 752-759.

Snowdon DA, Greiner LH, Mortimer JA et al. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA, 1997, 277: 813-817.

Левин О.С. Диагностика и лечение деменции в клинической практике. М.: Медпресс-информ, 2009, 255 с.

Левин О.С. Современные подходы к диагностике и лечению смешанной деменции. Трудный пациент, 2014, 5(12): 40-46.

Парфенов В.А., Захаров В.В., Преображенская И.С. Когнитивные расстройства. М., Группа РЕМЕДИУМ, 2014, 187 с.

Lemstra AW, Eikelenboom P, van Gool WA. The cholinergic deficiency syndrome and its therapeutic implications. Gerontology, 2003 Jan-Feb, 49(1): 55-60.

Ballard C, Sauter M, Scheltens P et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VanntagE study. Current Medical Research and Opinion, 2008, 24: 2561-2574.

Moretti R, Torre P, Antonello R. Rivastigmine superior to aspirin plus nimodipine in subcorti-cal vascular dementia: an open, 16-month, comparative study. International journal of clinical practice, 2004, 58: 346-353.

Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology, 2003 Apr 8, 60(7): 1183-5.

Engelhardt E, Moreira DM, Alves GS, Lanna ME, Alves CE, Ericeira-Valente L, et al. Binswanger’s disease and quantitative fractional anisotropy. Arq Neuropsiquiatr, 2009 Jun, 67(2A): 179-84.

Pugh KG, Lipsitz LA. The microvascular frontal– subcortical syndrome of aging. Neurobiol Aging, 2002 May-Jun, 23(3): 421-31.

Tullberg M, Ziegelitz D, Ribbelin S, Ekholm S. White matter diffusion is higher in Binswanger disease than in idiopathic normal pressure hydrocephalus. Acta Neurol Scand, 2009 Oct, 120(4): 226-34 Oct.

Shanks M, Kivipelto M, Bullock R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Current Medical Research and Opinion, 2009, 25: 2439-2446.

Zekry D, Gold G. Management of Mixed Dementia. Drugs and Aging, 2010, 27: 715-728.

Kavanagh S, Howe I, Brashear HR et al. Long-Term Response to Galantamine in Relation to Short-Term Efficacy Data: Pooled Analysis in Patients with Mild to Moderate Alzheimer’s Disease. Current Alzheimer Research, 2011, 8(1).

Rowland JP, Rigby J, Harper AC, Rowland R. Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol. Advances in Psychiatric Treatment, 2007, 13: 178-184.

Литвиненко И.В., Леонова Е.В. Терапевтические аспекты нарушения циркадного ритма высвобождения ацетилхолина при деменции. Пожилой пациент, 2009, 1: 31-35.

Goldsmith DR, Scott LJ. Donepezil in vascular dementia. Drugs Aging, 2003, 20: 1127-1136.

Ballard CG, Chalmers KA, Todd C et al. Cholinesterase inhibitors reduce cortical AB in dementia with Lewy bodies. Neurology, 2007, 68: 1726-1729.

Orgogozo J-M. Treatment of Alzheimer’s disease with cholinesterase inhibitors. An update on currently used drugs. /In: Alzheimer’s Disease and Related Disorders: Research Advances. Ed. by K. Iqbal and B. Winblad. Bucharest: Ana Aslan, 2003: 663-675.

Dooley M, Lamb HM Donepezil. A review of its use in Alzheimer’s disease. Drugs & Aging, 2000, 16: 199-226.

Jones RW, Soininen H, Hager K et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer’s disease. Int. J. Geriatr. Psychiat., 2004, 19: 58-67.

Wilkinson D, Doody R, Helme R et al. Donepezil in vascular dementia: A randomized, placebo-controlled study. Neurology, 2003, 61: 479-486.

Lanctot KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. Can. Med. Ass. J., 2003, 169: 557-564.

Waknine Y. FDA Approves High-Dose Donepezil for Advanced Alzheimer’s Disease CME/CE Released: 8/13/2010.

Delrieu J, Piau A, Caillaud C et al. Managing cognitive dysfunction through the continuum of Alzheimer’s disease. Role of pharmacotherapy. CNS Drugs, 2011, 25: 213-226.

Bourin M., Ripoll N., Dailly E. Nicotinic receptors and Alzheimer’s disease. Curr. Med. Res. Opin., 2003, 19(3): 1-9.

Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: A report of three cases. Neurology, 2000, 55: 870-871.

Hornung OP, Regen F, Dorn H et al. The effects of donepezil on postlearning sleep EEG of healthy older adults. Pharmacopsychiatry, 2009, 42: 9-13.

Takada Y, Yonezawa A, Kume T et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther., 2003, 306: 772-777.

Benarroch EE. Acetylcholine in the cerebral cortex: Effects and clinical implications. Neurology, 2010, 75: 659-665.

Люсов В.А., Постнов И. Ю., Орлов С.Н., Ряжский Г. Г. Различия в величине NA+-LI+-ПТ в мембране эритроцитов у больных гипертонической болезнью и почечной гипертензией. Кардиология, 1983, 13(8): 24-27.

Ослопов В.Н. Значение мембранных нарушений в развитии гипертонической болезни: Дисс. на соискание уч. ст. докт. мед. наук. Казань, 1995. 492 с.

Постнов И.Ю., Люсов В.А., Казеев К.Н. Проницаемость мембраны эритроцитов для натрия при гипертонической болезни и симптоматических гипертензиях. Кардиология, 1985, 4: 52-55.

Постнов Ю.В., Орлов С.Н. Первичная гипертензия как патология клеточных мембран. М., 1987. 190 с.

Petrov VV, Arabidze CG, Levitsky DO, Eliceev AO. Red blood cell sodium—lithium countertrans-port in patients with essential and renal hypertension. Methods Find. Exp. Clin. Pharmacol., 1994, 16: 153-157.

Биллах Х.М., Хасанов Н.Р., Ослопов В.Н., Чугунова Д.Н. Ионотранспортная функция клеточных мембран и показатели липидного профиля у больных гипертонической болезнью и здоровых лиц. Практическая медицина, 2013 сентябрь, 1-4(73): 113-116.

Kosmidou MS, Hatzitolios AI. Effects of Atorvastatin on Red-blood Cell Na+/Li+-Countertransport in Hyperlipidemic Patients With and Without Hypertension. American Journal of Hypertension, 2008, 21: 303-309.

Savopoulos CG. P-412: Sodium-lithium countertransport activity of red blood cells (SLC) in patients with essential hypertension (EH) and dyslipidaemia (D). Am. J. Hypertens., 2003, 16: 186A.

Stephenson SH, Hopkins PN. A prospective study of sodium-lithium countertransport and hypertension in Utah. Hypertension, 1991, 17: 1-7.

Мухутдинова Э.М. Особенности течения острого периода ишемического инсульта у пациентов с различным уровнем трансмембранного ионотранспорта. Дисс. канд. мед. наук. Казань, 2011.

Хасанов Н.Р. Генетические аспекты гипертонической болезни и подходов к антигипертензивной терапии. Дисс. доктора мед наук. Казань, 1995.

Canessa M, Adragna N, Solomon HS, Connoly TM. Increased sodium-lithium countertransport in red cells of patients with essential hypertension. N. Engl. J. Med., 1980, 302: 772-776.

Ослопов В.Н. Значение мембранных нарушений в развитии гипертонической болезни. Дисс. доктора мед наук. Казань, 1995.

Хасанова Д.Р. Мембранные основы синдромов вегетативной дисфункции. Дисс. доктора мед наук. Казань, 1999.

Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology, 2007, Dec 11, 69(24): 2197-204.

Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol Aug, 2009, 66(2): 200-8.

Zekry D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc., 2002, 50: 1431-1438.

Looi JC, Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology, 1999, Sep 11, 53(4): 670-8.

Hedden T, Mormino EC, Amariglio RE et al. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. The Journal of Neuroscience, 2012,November 14, 32(46): 16233-16242.

Debette S, Marcus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ, 2010, 341: c3666 doi:10.1136/bmj.c3666..
DOI: 10.1136/bmj.c3666

Ma Y, Zhang S, Li J et al Predictive Accuracy of Amyloid Imaging for Progression From Mild Cognitive Impairment to Alzheimer Disease With Different Lengths of Follow-up. Medicine, 2014 December, 93(27).

Емелин А.Ю. Когнитивные нарушения при цереброваскулярной болезни (патогенез, клиника, дифференциальная диагностика). Автореферат на соискание ученой степени доктора медицинских наук, 2010. 331 с.